Watchlist

Watchlist
Adaptimmune Therapeutics plc (ADAP)
Adaptimmune Therapeutics plc (ADAP)
Adaptimmune's SPEAR cells pass safety review in NSCLC study; dose to be raised; shares up 1% premarket
Adaptimmune Therapeutics plc (NASDAQ: ADAP ) is up 1% premarket on light volume after it announced a favorable review of the safety of 1B transduced SPEAR T-cells targeting MAGE-A10 in its non-small cell lung cancer (NSCLC) study. More news on: Adaptimmune Therapeutics plc, H…
Adaptimmune Therapeutics plc (ADAP)